TY - JOUR
T1 - Implementation of amulticenter biobanking collaboration for next-generation sequencing-based biomarker discovery based on fresh frozen pretreatment tumor tissue biopsies
AU - Bins, Sander
AU - Cirkel, Geert A.
AU - Gadellaa-Van Hooijdonk, Christa G.
AU - Weeber, Fleur
AU - Numan, Isaac J.
AU - Bruggink, Annette H.
AU - van Diest, Paul J.
AU - Willems, Stefan M.
AU - Veldhuis, Wouter B.
AU - van den Heuvel, Michel M.
AU - de Knegt, Rob J.
AU - Koudijs, Marco J.
AU - van Werkhoven, Erik
AU - Mathijssen, Ron H.J.
AU - Cuppen, Edwin
AU - Sleijfer, Stefan
AU - Schellens, Jan H.M.
AU - Voest, Emile E.
AU - Langenberg, Marlies H.G.
AU - de Jonge, Maja J.A.
AU - Steeghs, Neeltje
AU - Lolkema, Martijn P.
N1 - Publisher Copyright:
© AlphaMed Press 2017.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Background. The discovery of novel biomarkers that predict treatment response in advanced cancer patients requires acquisition of high-quality tumor samples. As cancer evolves over time, tissue is ideally obtained before the start of each treatment. Preferably, samples are freshly frozen to allow analysis by next-generation DNA/RNA sequencing (NGS) but also for making other emerging systematic techniques such as proteomics and metabolomics possible. Here, we describe the first 469 image-guided biopsies collected in a large collaboration in The Netherlands (Center for Personalized Cancer Treatment) and show the utility of these specimens for NGS analysis. Patients and Methods. Image-guided tumor biopsies were performed in advanced cancer patients. Samples were fresh frozen, vital tumor cellularity was estimated, and DNA was isolated after macrodissection of tumor-rich areas. Safety of the image-guided biopsy procedures was assessed by reporting of serious adverse events within 14 days after the biopsy procedure. Results. Biopsy procedures were generally well tolerated.Major complications occurred in 2.1%, most frequently consisting of pain. In 7.3% of the percutaneous lung biopsies, pneumothorax requiring drainage occurred. The majority of samples (81%) contained a vital tumor percentage of at least 30%, from which at least 500 ng DNA could be isolated in 91%. Given our preset criteria, 74% of samples were of sufficient quality for biomarker discovery. The NGS results in this cohort were in line with those in other groups. Conclusion. Image-guided biopsy procedures for biomarker discovery to enable personalized cancer treatment are safe and feasible and yield a highly valuable biobank.
AB - Background. The discovery of novel biomarkers that predict treatment response in advanced cancer patients requires acquisition of high-quality tumor samples. As cancer evolves over time, tissue is ideally obtained before the start of each treatment. Preferably, samples are freshly frozen to allow analysis by next-generation DNA/RNA sequencing (NGS) but also for making other emerging systematic techniques such as proteomics and metabolomics possible. Here, we describe the first 469 image-guided biopsies collected in a large collaboration in The Netherlands (Center for Personalized Cancer Treatment) and show the utility of these specimens for NGS analysis. Patients and Methods. Image-guided tumor biopsies were performed in advanced cancer patients. Samples were fresh frozen, vital tumor cellularity was estimated, and DNA was isolated after macrodissection of tumor-rich areas. Safety of the image-guided biopsy procedures was assessed by reporting of serious adverse events within 14 days after the biopsy procedure. Results. Biopsy procedures were generally well tolerated.Major complications occurred in 2.1%, most frequently consisting of pain. In 7.3% of the percutaneous lung biopsies, pneumothorax requiring drainage occurred. The majority of samples (81%) contained a vital tumor percentage of at least 30%, from which at least 500 ng DNA could be isolated in 91%. Given our preset criteria, 74% of samples were of sufficient quality for biomarker discovery. The NGS results in this cohort were in line with those in other groups. Conclusion. Image-guided biopsy procedures for biomarker discovery to enable personalized cancer treatment are safe and feasible and yield a highly valuable biobank.
KW - Advanced cancer patients
KW - Feasibility and safety
KW - Image-guided biopsy procedures
KW - Next-generation sequencing
KW - Personalized cancer treatment
KW - Precision oncology
UR - http://www.scopus.com/inward/record.url?scp=85011320216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011320216&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2016-0085
DO - 10.1634/theoncologist.2016-0085
M3 - Article
C2 - 27662884
AN - SCOPUS:85011320216
SN - 1083-7159
VL - 22
SP - 33
EP - 40
JO - Oncologist
JF - Oncologist
IS - 1
ER -